Y-Mabs Therapeutics Said It Is Internally Realigning Operations With The Establishment Of Two Business Units: Radiopharmaceuticals And Danyelza And Announced 2025 Priorities
Y-Mabs Therapeutics Said It Is Internally Realigning Operations With The Establishment Of Two Business Units: Radiopharmaceuticals And Danyelza And Announced 2025 Priorities
Y-mAbs Therapeutics表示，它正在通过成立两个业务单位（放射药物和Danyelza）来内部重新调整运营，并宣布2025年的优先事项。
- Company establishes two business units with goal of accelerating the advancement of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA
- Preliminary Part A data from GD2-SADA Phase 1 trial demonstrates tolerability and validity of SADA PRIT platform pre-targeting approach; Company expects to present Part A data in the second quarter of 2025
- Company reports preliminary estimated unaudited Total Net Revenue of approximately $88 million for the year ended December 31, 2024, within Full Year 2024 top line guidance range
- Company reports preliminary estimated unaudited cash, cash equivalents and marketable securities of approximately $67 million as of December 31, 2024, anticipated to support operations into 2027
- 公司建立两个业务部门，旨在加快其放射药物平台的发展并优化DANYELZA的商业潜力
- GD2-SADA 1期试验的初步A部分数据表明SADA PRIt平台预靶向方法的耐受性和有效性；公司预计将在2025年第二季度公布A部分数据
- 公司报告截至2024年12月31日的初步估计未经审计的总营业收入约为8800万，位于2024年全年顶部指导区间内
- 公司报告截至2024年12月31日的初步估计未经审计的现金、现金等价物和可市场证券约为6700万，预计支持运营到2027年
资讯热榜
更新时间